Maladie de reflux ­gastro-­œsophagien en 2024 [Gastroesophageal reflux disease in 2024]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 28/02/2026.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_C6AB966A31CF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Maladie de reflux ­gastro-­œsophagien en 2024 [Gastroesophageal reflux disease in 2024]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Dalex M., Schoepfer A.M., Wakim El-Khoury J.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
28/08/2024
Peer-reviewed
Oui
Volume
20
Numéro
884
Pages
1464-1468
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Gastroesophageal reflux disease is the most frequent gastroente-rological diagnosis, with a high prevalence of symptoms impacting patients' quality of life and causing high economic costs. It has a -complex pathophysiology that encompasses different mechanisms and an overlap with functional disorders that cause similar symptoms. Hence, an accurate diagnosis and phenotyping of patients is crucial to individualize therapy and limit health costs. Nowadays, therapy is personalized and encompasses lifestyle interventions, proton pump inhibitors, surgery, neuromodulation, diaphragmatic breathing as well as, in the future, new drugs and endoscopic interventions.
Mots-clé
Humans, Gastroesophageal Reflux/diagnosis, Gastroesophageal Reflux/therapy, Gastroesophageal Reflux/physiopathology, Gastroesophageal Reflux/epidemiology, Quality of Life, Proton Pump Inhibitors/therapeutic use, Prevalence, Life Style
Pubmed
Création de la notice
06/09/2024 15:54
Dernière modification de la notice
07/09/2024 6:17
Données d'usage